Ophthotech has posted negative results from a third phase 3 trial of its wet AMD candidate.

James Mullen has teamed up with colleagues from Biogen to help U.S. biotechs bring drugs to market in Europe.

The action furthers recently installed GSK CEO Emma Walmsley’s plan to purge the Big Pharma of its rare disease programs.

Belgian biotech Galapagos has chalked up a positive phase 2a trial for its idiopathic pulmonary fibrosis (IPF) drug GLPG1690, saying it halted the relentless…

The deal sees CRUK take a stake in the biotech in return for help testing a 5T4-CD3 bispecific antibody in patients with solid tumors.

Roivant Sciences, the parent company of the “Vant” family of biotechs, has secured a massive $1.1 billion investment.

Here's Wednesday's prescription for your biopharma news of note.

Ardelyx is cutting its workforce by nearly one-third as it looks to sharpen its focus on its phase 3 candidates.

The regimen lowered LDL cholesterol by 64%, a bigger drop than the combination of Zetia and Lipitor has achieved in other studies.